The Cosentyx drug market is mainly driven by the growing prevalence of psoriasis and psoriatic arthritis globally. Cosentyx is a human monoclonal antibody used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by selectively binding to interleukin-17A (IL-17A), preventing it from inducing inflammation. Cosentyx provides long-lasting relief from pain, swelling, and stiffness associated with these conditions. It offers rapid improvement in skin clear and suppresses inflammation more effectively than other biologic therapies. The drug has a favorable safety profile and is generally well tolerated with minimal adverse effects.

The Global Cosentyx Drug Market Is Estimated To Be Valued At US$ 5.32 Bn In 2024 And Is Expected To Exhibit A CAGR Of 7.3% Over The Forecast Period 2024 To 2031.

Key Takeaways

Key players operating in the Cosentyx drug market are Novartis AG. Novartis AG dominates the market with over 90% market share. The company is investing heavily in expanding its Cosentyx portfolio globally.

The Cosentyx Drug Market Demand is rapidly driven by the increasing cases of psoriasis and psoriatic arthritis worldwide. According to reports, over 125 million people globally suffer from psoriasis. The prevalence of the disease is increasing due to changing lifestyles and rising environmental stressors.

Novartis AG is actively expanding Cosentyx's global availability. The drug has gained regulatory approvals in over 80 countries and is being used to treat patients across major markets. Novartis aims to introduce Cosentyx in more developing nations to increase its patient reach.

Market Drivers

One of the major drivers for the Cosentyx Drug Market Size and Trends is the increasing failure rate of traditional biologic drugs such as TNF inhibitors. A significant percentage of psoriasis and arthritis patientsdo not respond fully or develop resistance to TNF inhibitor therapies over time. This has increased the demand for next-generation IL-17A inhibitor drugs such as Cosentyx that provide better efficacy.Moreover, Cosentyx's superior safety profile compared to traditional drugs is driving its adoption among healthcare professionals and patients.

The current geopolitical instability and uncertainty arising due to the Russia-Ukraine conflict is impacting the growth of the Cosentyx drug market. Both Russia and Ukraine contribute significantly to the global pharmaceutical supply chain. The conflict has disrupted supplies of raw materials and active pharmaceutical ingredients (APIs) which are key inputs for drug manufacturing. This has strained production capacities of drug makers and supply availability. Further restrictions on Russia due to sanctions are also impacting API trade.

Rising commodity prices and supply chain disruptions caused by the conflict have increased operating costs for drug companies substantially. Higher costs are affecting profit margins and companies may need to pass on some of these cost increases to customers through price hikes. This could impact demand and the adoption of expensive drugs like Cosentyx in the long run especially in cost sensitive markets.

To ensure stable supplies and sustainable growth, drug makers will need to diversify their sourcing networks and reduce dependencies on single or high risk regions for critical inputs. Companies may look to source more from friendly countries in Europe, North America and Asia. Investing in domestic manufacturing capabilities especially for essential ingredients can provide an impetus to 'Make in Country' strategies. Collaborations with local partners can help mitigate risks arising from geopolitical tensions.

The Cosentyx drug market is currently concentrated in regions like North America and Europe which account for sizeable shares in terms of value. North America alone contributes over 40% to the global market value due to large volumes sold and higher drug prices in the US. The availability of supportive reimbursement schemes has aided market growth in the region. Meanwhile, Europe is the second largest market benefiting from strong sales across major countries like Germany, UK and France.

However, the Asia Pacific region excluding Japan is emerging as the fastest growing market for Cosentyx. Increasing access to healthcare, rising disposability incomes, growing awareness about biologics and presence of patient support programs are fueling strong double digit growth rates. China in particular presents significant opportunities due to a large patient population and focus on developing domestic biopharmaceutical capacities. Investments into sales and marketing initiatives can further assist market penetration in high potential Asian markets over the coming years.

Get more insights: Cosentyx Drug Market

About Author:

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.

(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)

Get more insights: Cosentyx Drug Market